VERONA PHARMA PLC - ADR (VRNA)
US9250501064 - ADR
VERONA PHARMA PLC - ADR
NASDAQ:VRNA (12/20/2024, 4:12:53 PM)
After market: 42.02 0 (0%)42.02
+0.8 (+1.94%)
Company Profile
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. The firm is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. The company is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The firm's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The firm's wholly owned subsidiary is Verona Pharma, Inc.
Company Info
VERONA PHARMA PLC - ADR
Riverside, 3 More London Place
London SE1 2RE
P: 442032834200
CEO: David Zaccardelli
Employees: 79
Website: https://www.veronapharma.com/
VRNA News
a month ago - Verona Pharma plcVerona Pharma Announces December 2024 Investor Conference ParticipationLONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior...
2 months ago - Verona Pharma plcVerona Pharma to Present at Jefferies London Healthcare ConferenceLONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior...
2 months ago - Verona Pharma plcVerona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateOhtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique...
2 months ago - Verona Pharma plcVerona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate UpdateLONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will...
3 months ago - Verona Pharma plcVerona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024Verona Pharma announces four oral presentations and two posters on analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) at CHEST 2024. ...
3 months ago - Investor's Business DailyRegeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For DupixentThe FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD.
VRNA Twits
Here you can normally see the latest stock twits on VRNA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
